^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Case Comprehensive Cancer Center
    New trial
    1d
    Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) (clinicaltrials.gov)
    P2/3, N=175, Recruiting, GE Healthcare | Initiation date: May 2026 --> Oct 2026
    Trial initiation date
    4d
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    6d
    CX3CR1-Dependent Macrophages Drive Ovarian Cancer Progression Through MMP-2 and TGF-β Production. (PubMed, Cancers (Basel))
    The CX3CL1-CX3CR1 axis promotes ovarian cancer progression by recruiting MMP-2- and TGF-β-producing macrophages. Targeting CX3CR1-dependent TAM functions may represent a therapeutic strategy for limiting peritoneal dissemination in ovarian cancer.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • TGFB1 (Transforming Growth Factor Beta 1) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    6d
    Development of a prognostic model for postoperative survival in appendiceal pseudomyxoma peritonei based on clinical indicators. (PubMed, World J Surg Oncol)
    Histological type, preoperative PCI, CA125, LINS, and CC score are independent prognostic factors in appendiceal PMP. The developed nomogram offers accurate survival predictions and can be updated with new data for improved clinical decision-making.
    Retrospective data • Journal
    |
    LINS1 (Lines Homolog 1)
    6d
    Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study. (PubMed, Gynecol Oncol)
    NACT with atezolizumab was feasible and did not delay ICS. Translational parameters showed heterogeneous changes reflecting both immune activation and adaptive immune resistance.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel
    6d
    Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=46, Completed, Genelux Corporation | Phase classification: P1b --> P1/2
    Phase classification • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • olvimulogene nanivacirepvec (GL-ONC1)
    8d
    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=21, Recruiting, University of Chicago | Trial completion date: Jun 2026 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Jun 2030
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • mitomycin
    9d
    Retroperitoneal Malignant Triton Tumor in a 6-Year-Old Child Mimicking Wilms Tumor: A Case Report. (PubMed, Int Med Case Rep J)
    Despite palliative chemotherapy (cyclophosphamide and vincristine), the patient experienced rapid tumor recurrence and progressive clinical deterioration, culminating in death three weeks post-intervention. In resource-limited settings, where advanced molecular diagnostics are scarce, maintaining a high index of clinical suspicion and ensuring multidisciplinary management are paramount. Early histopathological confirmation is critical to addressing the rapid progression and therapeutic resistance characteristic of this malignancy.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    cyclophosphamide • vincristine
    16d
    GLORIOSA: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, AbbVie | Trial primary completion date: May 2032 --> Apr 2027
    Trial primary completion date • Platinum sensitive
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    16d
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    lorigerlimab (MGD019)
    17d
    Spectral CT iodine quantification for peritoneal metastasis burden and resectability prediction in ovarian cancer: a retrospective cohort study. (PubMed, Front Oncol)
    Spectral CT iodine quantification demonstrates potential as a complementary tool for estimating peritoneal metastasis burden and predicting surgical resectability. The NIC threshold of 0.55 shows promise for stratifying patients, though external validation is needed before integration into preoperative staging protocols.
    Retrospective data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)